Nimbus Therapeutics is excited to announce the successful completion of a substantial funding round, securing $210 million to enhance its groundbreaking work in drug discovery. As a clinical-stage company, Nimbus is at the forefront of developing novel small molecule medicines aimed at challenging yet critical targets associated with numerous human diseases. With this latest financial boost, Nimbus will accelerate its innovative research strategies that uniquely blend advanced computational technologies with cutting-edge machine learning predictive modeling. This approach allows the company to explore and develop therapeutics for conditions that have long resisted conventional treatment efforts. The funding will primarily support Nimbus’ promising clinical-stage HPK1 inhibitor aimed at treating cancer, which is currently undergoing rigorous testing (NCT05128487). Additionally, the capital will also propel the advancement of the company's exciting pipeline of preclinical programs, including projects focused on WRN for MSI-H cancers, autoimmune conditions, and metabolic diseases. Nimbus Therapeutics remains dedicated to transforming the landscape of drug development by leveraging their robust technological platform to deliver impactful therapies for patients with severe unmet needs. With this significant investment, Nimbus is poised to expand its reach and enhance its capabilities, driving forward its mission to bring forth precision medicine solutions that can profoundly improve patient outcomes in oncology and beyond.
Breaking News: Nimbus Therapeutics Secures $210M in Funding for Groundbreaking Drug Discovery
Recently funded · $210.0MPharmaceuticals
Get the full Nimbus Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
